HESTIA (HPV-16/18 E6/E7-specific T lymphocytes)

HPV-16/18 E6/E7-specific T lymphocytes · Baylor College of Medicine

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HESTIA (HPV-16/18 E6/E7-specific T lymphocytes), covering 2026-04-15 to 2026-04-15. Get the full timeline:

Most recent: Clinical Trial Update: HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA [Phase 1]